Clinical trial · Observational
Liver Resection for Patients With Hepatocellular Carcinoma and Impaired Liver Function
Liver Resection for Patients With Hepatocellular Carcinoma and Impaired Liver Function: A Chinese Multicenter Observational Study
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Hepatic dysfunction limits the therapeutic options for hepatocellular carcinoma (HCC), which is closely associated with patient prognosis. Established practice guidelines for patients with HCC and impaired liver function are lacking. The treatment allocation in these populations is heterogeneous and remains controversial. This study compared the survival benefits of liver resection (LR) and transarterial chemoembolisation (TACE) in patients with HCC and impaired liver function.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Hepatic Cancer | Liver Neoplasm | ONTOLOGY_EXACT | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| transarterial chemoembolisation | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- label
- liver resection
- label
- transarterial chemoembolisation
- interventionNames
- Procedure: transarterial chemoembolisation
Primary outcomes (1)
- measure
- overall survival
- timeFrame
- 5 year
- description
- The overall survival rate at 5 years
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * patients with HCC who received conventional LR or TACE Exclusion Criteria: * （1） presence of portal vein tumour thrombosis (PVTT), hepatic artery, biliary duct or inferior vena cava invasion * （2） extrahepatic spread (EHS) * （3） albumin-bilirubin grade 1 or 3 * （4） Eastern Cooperative Oncology Group Performance Status (ECOG-PS) \>1 * （5） tumour number \>3 * （6） other tumours or severe cardiac, cerebral, and renal insufficiency * （7）ascites, hepatic encephalopathy, and jaundice
References
Publications (0)
Data not yet available